Xianshen Pharma Partners with Schrödinger on Global Drug Discovery; 10 Marketed Drugs and 60+ Pipeline Assets

According to Zhitong Finance, Xianshen Pharma (02096) announced on July 10 a global drug discovery and development partnership with Schrödinger, a leading AI technology platform. The collaboration will leverage Schrödinger's physics-based and AI-driven drug design platform alongside Xianshen's expertise in neuroscience, oncology, autoimmune diseases, and anti-infection therapies.

As of 2025, Xianshen Pharma has 10 marketed innovative drugs and over 60 drugs in development. The company reported that innovative drug revenue accounted for 81.5% of total revenue in 2025, supported by approximately 9 billion yuan in research and development investment over the past five years.